{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:44:04Z","timestamp":1783791844666,"version":"3.55.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Basic Res Cardiol"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:p>Current myocarditis guidelines do not advocate treatment to prevent myocardial injury and scar deposition in patients with myocarditis and normal left ventricular ejection fraction. We aimed to ascertain the utility of beta blockers, calcium channel blockers and antagonists of the renin\u2013angiotensin system in ameliorating myocardial injury, scar formation and calcification in animal in vivo models of myocarditis. The project was prospectively registered with the PROSPERO database of systematic reviews (CRD42018089336). Primary outcomes (necrosis, fibrosis and calcification) were meta-analysed with random-effects modelling. 52 studies were systematically reviewed. Meta-analysis was performed compared with untreated controls. In each study, we identified all independent comparisons of treatment versus control groups. The pooled weighted mean difference (WMD) indicated treatment reduced necrosis by 16.9% (71 controlled analyses, 95% CI 13.2\u201320.7%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), however there was less evidence of an effect after accounting for publication bias. Treatment led to a 12.8% reduction in fibrosis (73 controlled analyses, 95% CI 7.6\u201318.0%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). After accounting for publication bias this was attenuated to 7.8% but remained significant. Treatment reduced calcification by 4.1% (28 controlled analyses, 95% CI 0.2\u20138.0%; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0395). We observed significant heterogeneity in effect size in all primary endpoints, which was predominantly driven by differences between drug categories. Beta blockers and angiotensin-converting enzyme (ACE) inhibitors were the only agents that were effective for both necrosis and fibrosis, while only ACE inhibitors had a significant effect on calcification. This study provides evidence for a role for ACE inhibitors and beta blockers to prevent myocardial injury and scar deposition in in vivo models of myocarditis. There is a need for further well-designed studies to assess the translational application of these treatments.<\/jats:p>","DOI":"10.1007\/s00395-019-0754-x","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T19:05:28Z","timestamp":1572548728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Therapies to limit myocardial injury in animal models of myocarditis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"114","author":[{"given":"Joshua A.","family":"Silverblatt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver J.","family":"Ziff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Dancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Sado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Bromage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"754_CR1","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.CIR.93.5.841","volume":"93","author":"P Richardson","year":"1996","unstructured":"Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O\u2019Connell J, Olsen E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P (1996) Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93:841\u2013842","journal-title":"Circulation"},{"key":"754_CR2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","volume":"34","author":"AL Caforio","year":"2013","unstructured":"Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss HP, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM, European Society of Cardiology Working Group on M, Pericardial D (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34:2636\u20132648. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/eht210","journal-title":"Eur Heart J"},{"key":"754_CR3","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/eurheartj\/ehm076","volume":"28","author":"AL Caforio","year":"2007","unstructured":"Caforio AL, Calabrese F, Angelini A, Tona F, Vinci A, Bottaro S, Ramondo A, Carturan E, Iliceto S, Thiene G, Daliento L (2007) A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28:1326\u20131333. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehm076","journal-title":"Eur Heart J"},{"key":"754_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1097\/00005792-199907000-00005","volume":"78","author":"GM Felker","year":"1999","unstructured":"Felker GM, Hu W, Hare JM, Hruban RH, Baughman KL, Kasper EK (1999) The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1278 patients. Medicine (Baltimore) 78:270\u2013283","journal-title":"Medicine (Baltimore)"},{"key":"754_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2011.09.074","volume":"59","author":"I Kindermann","year":"2012","unstructured":"Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, Klingel K, Kandolf R, Sechtem U, Cooper LT, Bohm M (2012) Update on myocarditis. J Am Coll Cardiol 59:779\u2013792. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2011.09.074","journal-title":"J Am Coll Cardiol"},{"key":"754_CR6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jama.2013.1363","volume":"309","author":"A Gulati","year":"2013","unstructured":"Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, Morarji K, Brown TD, Ismail NA, Dweck MR, Di Pietro E, Roughton M, Wage R, Daryani Y, O\u2019Hanlon R, Sheppard MN, Alpendurada F, Lyon AR, Cook SA, Cowie MR, Assomull RG, Pennell DJ, Prasad SK (2013) Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309:896\u2013908. \nhttps:\/\/doi.org\/10.1001\/jama.2013.1363","journal-title":"JAMA"},{"key":"754_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/CIRCULATIONAHA.116.026910","volume":"135","author":"BP Halliday","year":"2017","unstructured":"Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK (2017) Association between Midwall Late Gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 135:2106\u20132115. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.026910","journal-title":"Circulation"},{"key":"754_CR8","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/j.jacc.2017.08.044","volume":"70","author":"GD Aquaro","year":"2017","unstructured":"Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, Pepe A, Todiere G, Lanzillo C, Scatteia A, Di Roma M, Pontone G, Perazzolo Marra M, Barison A, Di Bella G, Cardiac Magnetic Resonance Working Group of the Italian Society of C (2017) Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY Study. J Am Coll Cardiol 70:1977\u20131987. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2017.08.044","journal-title":"J Am Coll Cardiol"},{"key":"754_CR9","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.jacc.2017.08.050","volume":"70","author":"C Grani","year":"2017","unstructured":"Grani C, Eichhorn C, Biere L, Murthy VL, Agarwal V, Kaneko K, Cuddy S, Aghayev A, Steigner M, Blankstein R, Jerosch-Herold M, Kwong RY (2017) Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70:1964\u20131976. \nhttps:\/\/doi.org\/10.1016\/j.jacc.2017.08.050","journal-title":"J Am Coll Cardiol"},{"key":"754_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.07.015","author":"BP Halliday","year":"2018","unstructured":"Halliday BP, Baksi AJ, Gulati A, Ali A, Newsome S, Izgi C, Arzanauskaite M, Lota A, Tayal U, Vassiliou VS, Gregson J, Alpendurada F, Frenneaux MP, Cook SA, Cleland JGF, Pennell DJ, Prasad SK (2018) Outcome in dilated cardiomyopathy related to the extent, location, and pattern of Late Gadolinium enhancement. JACC Cardiovasc Imaging. \nhttps:\/\/doi.org\/10.1016\/j.jcmg.2018.07.015","journal-title":"JACC Cardiovasc Imaging"},{"key":"754_CR11","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","volume":"36","author":"Y Adler","year":"2015","unstructured":"Adler Y, Charron P, Imazio M, Badano L, Baron-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K, Lionis C, Maisch B, Mayosi B, Pavie A, Ristic AD, Sabate Tenas M, Seferovic P, Swedberg K, Tomkowski W, Group ESCSD (2015) 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC) endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36:2921\u20132964. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehv318","journal-title":"Eur Heart J"},{"key":"754_CR12","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. \nhttps:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"754_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ajodo.2006.02.028","volume":"130","author":"C Flores-Mir","year":"2006","unstructured":"Flores-Mir C, Major MP, Major PW (2006) Search and selection methodology of systematic reviews in orthodontics (2000\u20132004). Am J Orthodont Dentofac Orthop 130:214\u2013217. \nhttps:\/\/doi.org\/10.1016\/j.ajodo.2006.02.028","journal-title":"Am J Orthodont Dentofac Orthop"},{"key":"754_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/sj.ebd.6400504","volume":"8","author":"MP Major","year":"2007","unstructured":"Major MP, Major PW, Flores-Mir C (2007) Benchmarking of reported search and selection methods of systematic reviews by dental speciality. Evid Based Dentist 8:66\u201370. \nhttps:\/\/doi.org\/10.1038\/sj.ebd.6400504","journal-title":"Evid Based Dentist"},{"key":"754_CR15","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.14219\/jada.archive.2006.0382","volume":"137","author":"MP Major","year":"2006","unstructured":"Major MP, Major PW, Flores-Mir C (2006) An evaluation of search and selection methods used in dental systematic reviews published in English. J Am Dent Assoc 137:1252\u20131257","journal-title":"J Am Dent Assoc"},{"key":"754_CR16","unstructured":"Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 510: the Cochrane Collaboration; 2011."},{"key":"754_CR17","doi-asserted-by":"publisher","first-page":"405","DOI":"10.14670\/HH-11-809","volume":"32","author":"M Atteya","year":"2017","unstructured":"Atteya M, Mohamed RA, Ahmed AM, Abdel-Baky NA, Alfayez MA, Almalke HD, El Fouhil AF (2017) Lisinopril has a cardio-protective effect on experimental acute autoimmune myocarditis in rats. Histol Histopathol 32:405\u2013412. \nhttps:\/\/doi.org\/10.14670\/HH-11-809","journal-title":"Histol Histopathol"},{"key":"754_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1365-3083.2009.02347.x","volume":"71","author":"H Liu","year":"2010","unstructured":"Liu H, Li W, Gu W, Kong Y, Yang N, Chen L (2010) Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. Scand J Immunol 71:38\u201344. \nhttps:\/\/doi.org\/10.1111\/j.1365-3083.2009.02347.x","journal-title":"Scand J Immunol"},{"key":"754_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1023\/B:MCBI.0000021379.82282.53","volume":"259","author":"M Nimata","year":"2004","unstructured":"Nimata M, Kishimoto C, Yuan Z, Shioji K (2004) Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 259:217\u2013222","journal-title":"Mol Cell Biochem"},{"key":"754_CR20","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.105.607903","volume":"114","author":"M Nishii","year":"2006","unstructured":"Nishii M, Inomata T, Niwano H, Takehana H, Takeuchi I, Nakano H, Shinagawa H, Naruke T, Koitabashi T, Nakahata J, Izumi T (2006) Beta2-Adrenergic agonists suppress rat autoimmune myocarditis: potential role of beta2-adrenergic stimulants as new therapeutic agents for myocarditis. Circulation 114:936\u2013944. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.607903","journal-title":"Circulation"},{"key":"754_CR21","doi-asserted-by":"publisher","first-page":"H2596","DOI":"10.1152\/ajpheart.00215.2008","volume":"294","author":"T Ogawa","year":"2008","unstructured":"Ogawa T, Veinot JP, Kuroski de Bold ML, Georgalis T, de Bold AJ (2008) Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am J Physiol Heart Circ Physiol 294:H2596\u20132603. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00215.2008","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"754_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/CS20050299","volume":"110","author":"Y Seko","year":"2006","unstructured":"Seko Y (2006) Effect of the angiotensin II receptor blocker olmesartan on the development of murine acute myocarditis caused by coxsackievirus B3. Clin Sci (Lond) 110:379\u2013386. \nhttps:\/\/doi.org\/10.1042\/CS20050299","journal-title":"Clin Sci (Lond)"},{"key":"754_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/1074248417725058","volume":"23","author":"M Skrzypiec-Spring","year":"2018","unstructured":"Skrzypiec-Spring M, Haczkiewicz K, Sapa A, Piasecki T, Kwiatkowska J, Ceremuga I, Wozniak M, Biczysko W, Kobierzycki C, Dziegiel P, Podhorska-Okolow M, Szelag A (2018) Carvedilol inhibits matrix metalloproteinase-2 activation in experimental autoimmune myocarditis: possibilities of cardioprotective application. J Cardiovasc Pharmacol Ther 23:89\u201397. \nhttps:\/\/doi.org\/10.1177\/1074248417725058","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"754_CR24","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.gene.2014.06.003","volume":"547","author":"D Wang","year":"2014","unstructured":"Wang D, Chen Y, Jiang J, Zhou A, Pan L, Chen Q, Qian Y, Chu M, Chen C (2014) Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene 547:195\u2013201. \nhttps:\/\/doi.org\/10.1016\/j.gene.2014.06.003","journal-title":"Gene"},{"key":"754_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejphar.2008.06.088","volume":"592","author":"JF Wang","year":"2008","unstructured":"Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, Abelmann WH, Green AI, Zeind J, Morgan JP (2008) Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol 592:123\u2013127. \nhttps:\/\/doi.org\/10.1016\/j.ejphar.2008.06.088","journal-title":"Eur J Pharmacol"},{"key":"754_CR26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1253\/circj.67.545","volume":"67","author":"Z Yuan","year":"2003","unstructured":"Yuan Z, Kishimoto C, Shioji K (2003) Beneficial effects of low-dose benidipine in acute autoimmune myocarditis: suppressive effects on inflammatory cytokines and inducible nitric oxide synthase. Circ J 67:545\u2013550","journal-title":"Circ J"},{"key":"754_CR27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/A:1024104906484","volume":"248","author":"Z Yuan","year":"2003","unstructured":"Yuan Z, Kishimoto C, Shioji K, Nakamura H, Yodoi J, Sasayama S (2003) Temocapril treatment ameliorates autoimmune myocarditis associated with enhanced cardiomyocyte thioredoxin expression. Mol Cell Biochem 248:185\u2013192","journal-title":"Mol Cell Biochem"},{"key":"754_CR28","doi-asserted-by":"publisher","first-page":"H1147","DOI":"10.1152\/ajpheart.00078.2005","volume":"289","author":"Z Yuan","year":"2005","unstructured":"Yuan Z, Nimata M, Okabe TA, Shioji K, Hasegawa K, Kita T, Kishimoto C (2005) Olmesartan, a novel AT1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 289:H1147\u20131152. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00078.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"754_CR29","doi-asserted-by":"publisher","first-page":"H83","DOI":"10.1152\/ajpheart.00536.2003","volume":"286","author":"Z Yuan","year":"2004","unstructured":"Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C (2004) Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 286:H83\u201390. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00536.2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"754_CR30","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.lfs.2013.05.010","volume":"92","author":"YY Zhang","year":"2013","unstructured":"Zhang YY, Li JN, Xia HH, Zhang SL, Zhong J, Wu YY, Miao SK, Zhou LM (2013) Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3. Life Sci 92:1186\u20131194. \nhttps:\/\/doi.org\/10.1016\/j.lfs.2013.05.010","journal-title":"Life Sci"},{"key":"754_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00005344-199507000-00010","volume":"26","author":"M Araki","year":"1995","unstructured":"Araki M, Kanda T, Imai S, Suzuki T, Murata K, Kobayashi I (1995) Comparative effects of losartan, captopril, and enalapril on murine acute myocarditis due to encephalomyocarditis virus. J Cardiovasc Pharmacol 26:61\u201365","journal-title":"J Cardiovasc Pharmacol"},{"key":"754_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1142\/S0192415X06004028","volume":"34","author":"XJ Chen","year":"2006","unstructured":"Chen XJ, Bian ZP, Lu S, Xu JD, Gu CR, Yang D, Zhang JN (2006) Cardiac protective effect of Astragalus on viral myocarditis mice: comparison with Perindopril. Am J Chin Med 34:493\u2013502. \nhttps:\/\/doi.org\/10.1142\/S0192415X06004028","journal-title":"Am J Chin Med"},{"key":"754_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.CIR.81.3.1039","volume":"81","author":"S Rezkalla","year":"1990","unstructured":"Rezkalla S, Kloner RA, Khatib G, Khatib R (1990) Beneficial effects of captopril in acute coxsackievirus B3 murine myocarditis. Circulation 81:1039\u20131046","journal-title":"Circulation"},{"key":"754_CR34","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/0002-8703(90)90251-R","volume":"120","author":"S Rezkalla","year":"1990","unstructured":"Rezkalla S, Kloner RA, Khatib G, Khatib R (1990) Effect of delayed captopril therapy on left ventricular mass and myonecrosis during acute coxsackievirus murine myocarditis. Am Heart J 120:1377\u20131381","journal-title":"Am Heart J"},{"key":"754_CR35","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/0735-1097(88)90414-7","volume":"12","author":"S Rezkalla","year":"1988","unstructured":"Rezkalla S, Kloner RA, Khatib G, Smith FE, Khatib R (1988) Effect of metoprolol in acute coxsackievirus B3 murine myocarditis. J Am Coll Cardiol 12:412\u2013414","journal-title":"J Am Coll Cardiol"},{"key":"754_CR36","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1172\/JCI116513","volume":"91","author":"H Suzuki","year":"1993","unstructured":"Suzuki H, Matsumori A, Matoba Y, Kyu BS, Tanaka A, Fujita J, Sasayama S (1993) Enhanced expression of superoxide dismutase messenger RNA in viral myocarditis. An SH-dependent reduction of its expression and myocardial injury. J Clin Invest 91:2727\u20132733. \nhttps:\/\/doi.org\/10.1172\/JCI116513","journal-title":"J Clin Invest"},{"key":"754_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","volume":"14","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW (2014) SYRCLE\u2019s risk of bias tool for animal studies. BMC Med Res Methodol 14:43. \nhttps:\/\/doi.org\/10.1186\/1471-2288-14-43","journal-title":"BMC Med Res Methodol"},{"key":"754_CR38","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/01.STR.0000125719.25853.20","volume":"35","author":"MR Macleod","year":"2004","unstructured":"Macleod MR, O\u2019Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke J Cereb Circ 35:1203\u20131208. \nhttps:\/\/doi.org\/10.1161\/01.STR.0000125719.25853.20","journal-title":"Stroke J Cereb Circ"},{"key":"754_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneumeth.2013.09.010","volume":"221","author":"HM Vesterinen","year":"2014","unstructured":"Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, Antonic A, Howells DW, Macleod MR (2014) Meta-analysis of data from animal studies: a practical guide. J Neurosci Methods 221:92\u2013102. \nhttps:\/\/doi.org\/10.1016\/j.jneumeth.2013.09.010","journal-title":"J Neurosci Methods"},{"key":"754_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. \nhttps:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"754_CR41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1093\/ilar\/ilu042","volume":"55","author":"CR Hooijmans","year":"2014","unstructured":"Hooijmans CR, IntHout J, Ritskes-Hoitinga M, Rovers MM (2014) Meta-analyses of animal studies: an introduction of a valuable instrument to further improve healthcare. ILAR J Natl Res Council Inst Lab Anim Resour 55:418\u2013426. \nhttps:\/\/doi.org\/10.1093\/ilar\/ilu042","journal-title":"ILAR J Natl Res Council Inst Lab Anim Resour"},{"key":"754_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R (2000) Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455\u2013463","journal-title":"Biometrics"},{"key":"754_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.lfs.2009.05.018","volume":"85","author":"W Liu","year":"2009","unstructured":"Liu W, Shimada M, Xiao J, Hu D, Matsumori A (2009) Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sci 85:235\u2013240. \nhttps:\/\/doi.org\/10.1016\/j.lfs.2009.05.018","journal-title":"Life Sci"},{"key":"754_CR44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.CIR.99.8.1091","volume":"99","author":"C Kawai","year":"1999","unstructured":"Kawai C (1999) From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99:1091\u20131100","journal-title":"Circulation"},{"key":"754_CR45","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/pmj.77.903.4","volume":"77","author":"MT Kearney","year":"2001","unstructured":"Kearney MT, Cotton JM, Richardson PJ, Shah AM (2001) Viral myocarditis and dilated cardiomyopathy: mechanisms, manifestations, and management. Postgrad Med J 77:4\u201310","journal-title":"Postgrad Med J"},{"key":"754_CR46","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","volume":"33","author":"F Zannad","year":"2012","unstructured":"Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O\u2019Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Pina IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33:2782\u20132795. \nhttps:\/\/doi.org\/10.1093\/eurheartj\/ehs257","journal-title":"Eur Heart J"},{"key":"754_CR47","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1096\/fj.05-4642fje","volume":"20","author":"S Johar","year":"2006","unstructured":"Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM (2006) Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20:1546\u20131548. \nhttps:\/\/doi.org\/10.1096\/fj.05-4642fje","journal-title":"FASEB J"},{"key":"754_CR48","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s000590050024","volume":"25","author":"CG Brilla","year":"2000","unstructured":"Brilla CG (2000) Aldosterone and myocardial fibrosis in heart failure. Herz 25:299\u2013306","journal-title":"Herz"},{"key":"754_CR49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2174\/1568016043356219","volume":"2","author":"D Fraccarollo","year":"2004","unstructured":"Fraccarollo D, Galuppo P, Bauersachs J (2004) Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. Curr Med Chem Cardiovasc Hematol Agents 2:287\u2013294","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"754_CR50","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1161\/01.CIR.0000068340.96506.0F","volume":"107","author":"M Hayashi","year":"2003","unstructured":"Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M (2003) Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 107:2559\u20132565. \nhttps:\/\/doi.org\/10.1161\/01.CIR.0000068340.96506.0F","journal-title":"Circulation"},{"key":"754_CR51","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","volume":"119","author":"W Iraqi","year":"2009","unstructured":"Iraqi W, Rossignol P, Angioi M, Fay R, Nuee J, Ketelslegers JM, Vincent J, Pitt B, Zannad F (2009) Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119:2471\u20132479. \nhttps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.809194","journal-title":"Circulation"},{"key":"754_CR52","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","volume":"106","author":"G Suzuki","year":"2002","unstructured":"Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN (2002) Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106:2967\u20132972","journal-title":"Circulation"},{"key":"754_CR53","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","volume":"102","author":"F Zannad","year":"2000","unstructured":"Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700\u20132706","journal-title":"Circulation"},{"key":"754_CR54","doi-asserted-by":"publisher","first-page":"e1000344","DOI":"10.1371\/journal.pbio.1000344","volume":"8","author":"ES Sena","year":"2010","unstructured":"Sena ES, van der Worp HB, Bath PM, Howells DW, Macleod MR (2010) Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 8:e1000344. \nhttps:\/\/doi.org\/10.1371\/journal.pbio.1000344","journal-title":"PLoS Biol"},{"key":"754_CR55","doi-asserted-by":"publisher","first-page":"e1000245","DOI":"10.1371\/journal.pmed.1000245","volume":"7","author":"HB van der Worp","year":"2010","unstructured":"van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O\u2019Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7:e1000245. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1000245","journal-title":"PLoS Med"},{"key":"754_CR56","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.yjmcc.2011.04.008","volume":"51","author":"HB van der Worp","year":"2011","unstructured":"van der Worp HB, Macleod MR (2011) Preclinical studies of human disease: time to take methodological quality seriously. J Mol Cell Cardiol 51:449\u2013450. \nhttps:\/\/doi.org\/10.1016\/j.yjmcc.2011.04.008","journal-title":"J Mol Cell Cardiol"},{"key":"754_CR57","doi-asserted-by":"publisher","first-page":"e98856","DOI":"10.1371\/journal.pone.0098856","volume":"9","author":"JA Hirst","year":"2014","unstructured":"Hirst JA, Howick J, Aronson JK, Roberts N, Perera R, Koshiaris C, Heneghan C (2014) The need for randomization in animal trials: an overview of systematic reviews. PloS One 9:e98856. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0098856","journal-title":"PloS One"},{"key":"754_CR58","doi-asserted-by":"publisher","first-page":"e0142021","DOI":"10.1371\/journal.pone.0142021","volume":"10","author":"KE Wever","year":"2015","unstructured":"Wever KE, Hooijmans CR, Riksen NP, Sterenborg TB, Sena ES, Ritskes-Hoitinga M, Warle MC (2015) Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies. PLoS One 10:e0142021. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0142021","journal-title":"PLoS One"},{"key":"754_CR59","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0024-3205(00)00654-8","volume":"67","author":"T Baba","year":"2000","unstructured":"Baba T, Kanda T, Kobayashi I (2000) Reduction of cardiac endothelin-1 by angiotensin II type 1 receptor antagonist in viral myocarditis of mice. Life Sci 67:587\u2013597","journal-title":"Life Sci"},{"key":"754_CR60","doi-asserted-by":"publisher","first-page":"H1564","DOI":"10.1152\/ajpheart.00126.2015","volume":"308","author":"G Teng","year":"2015","unstructured":"Teng G, Svystonyuk D, Mewhort HE, Turnbull JD, Belke DD, Duff HJ, Fedak PW (2015) Tetrandrine reverses human cardiac myofibroblast activation and myocardial fibrosis. Am J Physiol Heart Circ Physiol 308:H1564\u20131574. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00126.2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"754_CR61","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000078629","volume":"72","author":"MI Wahed","year":"2004","unstructured":"Wahed MI, Watanabe K, Ma M, Nakazawa M, Takahashi T, Hasegawa G, Naito M, Yamamoto T, Kodama M, Aizawa Y (2004) Effects of pranidipine, a novel calcium channel antagonist, on the progression of left ventricular dysfunction and remodeling in rats with heart failure. Pharmacology 72:26\u201332. \nhttps:\/\/doi.org\/10.1159\/000078629","journal-title":"Pharmacology"},{"key":"754_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000091746","volume":"77","author":"PT Veeraveedu","year":"2006","unstructured":"Veeraveedu PT, Watanabe K, Ma M, Gurusamy N, Palaniyandi SS, Wen J, Prakash P, Wahed MI, Kamal FA, Mito S, Kunisaki M, Kodama M, Aizawa Y (2006) Comparative effects of pranidipine with amlodipine in rats with heart failure. Pharmacology 77:1\u201310. \nhttps:\/\/doi.org\/10.1159\/000091746","journal-title":"Pharmacology"},{"key":"754_CR63","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","volume":"335","author":"M Packer","year":"1996","unstructured":"Packer M, O\u2019Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL (1996) Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 335:1107\u20131114. \nhttps:\/\/doi.org\/10.1056\/NEJM199610103351504","journal-title":"N Engl J Med"},{"key":"754_CR64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","volume":"83","author":"RE Goldstein","year":"1991","unstructured":"Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S (1991) Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 83:52\u201360","journal-title":"Circulation"},{"key":"754_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1023\/A:1007752310881","volume":"13","author":"M Yoshiyama","year":"1999","unstructured":"Yoshiyama M, Takeuchi K, Omura T, Izutani S, Nakamura Y, Akioka K, Kim S, Iwao H, Yoshikawa J (1999) Effect of diltiazem on cardiac remodeling in rats assessed by Doppler echocardiography and mRNA expression. Cardiovasc Drugs Ther 13:249\u2013258","journal-title":"Cardiovasc Drugs Ther"},{"key":"754_CR66","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1056\/NEJM199508033330501","volume":"333","author":"JW Mason","year":"1995","unstructured":"Mason JW, O\u2019Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269\u2013275. \nhttps:\/\/doi.org\/10.1056\/NEJM199508033330501","journal-title":"N Engl J Med"},{"key":"754_CR67","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/jmv.21928","volume":"82","author":"B Gluck","year":"2010","unstructured":"Gluck B, Dahlke K, Zell R, Krumbholz A, Decker M, Lehmann J, Wutzler P (2010) Cardioprotective effect of NO-metoprolol in murine coxsackievirus B3-induced myocarditis. J Med Virol 82:2043\u20132052. \nhttps:\/\/doi.org\/10.1002\/jmv.21928","journal-title":"J Med Virol"},{"key":"754_CR68","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0735-1097(02)02711-0","volume":"41","author":"R Nishio","year":"2003","unstructured":"Nishio R, Shioi T, Sasayama S, Matsumori A (2003) Carvedilol increases the production of interleukin-12 and interferon-gamma and improves the survival of mice infected with the encephalomyocarditis virus. J Am Coll Cardiol 41:340\u2013345","journal-title":"J Am Coll Cardiol"},{"key":"754_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/FJC.0b013e31815c6624","volume":"51","author":"L Yue-Chun","year":"2008","unstructured":"Yue-Chun L, Li-Sha G, Jiang-Hua R, Peng-Lin Y, Jia-Feng L, Ji-Fei T, Peng C, Zhan-Qiu Y (2008) Protective effects of carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. J Cardiovasc Pharmacol 51:92\u201398. \nhttps:\/\/doi.org\/10.1097\/FJC.0b013e31815c6624","journal-title":"J Cardiovasc Pharmacol"},{"key":"754_CR70","doi-asserted-by":"publisher","first-page":"e39394","DOI":"10.1371\/journal.pone.0039394","volume":"7","author":"L Yue-Chun","year":"2012","unstructured":"Yue-Chun L, Teng Z, Na-Dan Z, Li-Sha G, Qin L, Xue-Qiang G, Jia-Feng L (2012) Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis. PLoS One 7:e39394. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0039394","journal-title":"PLoS One"},{"key":"754_CR71","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0022-3468(94)90074-4","volume":"29","author":"A Stallion","year":"1994","unstructured":"Stallion A, Rafferty JF, Warner BW, Ziegler MM, Ryckman FC (1994) Myocardial calcification: a predictor of poor outcome for myocarditis treated with extracorporeal life support. J Pediatr Surg 29:492\u2013494","journal-title":"J Pediatr Surg"},{"key":"754_CR72","unstructured":"ClinicalTrials.gov. \nhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02740179?term=miracle+hiv&rank=1\n\n. Accessed 23 Apr 2019"},{"key":"754_CR73","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10557-007-6024-4","volume":"21","author":"S Saegusa","year":"2007","unstructured":"Saegusa S, Fei Y, Takahashi T, Sumino H, Moriya J, Kawaura K, Yamakawa J, Itoh T, Morimoto S, Nakahashi T, Iwai K, Matsumoto M, Kanda T (2007) Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther 21:155\u2013160. \nhttps:\/\/doi.org\/10.1007\/s10557-007-6024-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"754_CR74","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1161\/01.CIR.95.1.245","volume":"95","author":"WZ Wang","year":"1997","unstructured":"Wang WZ, Matsumori A, Yamada T, Shioi T, Okada I, Matsui S, Sato Y, Suzuki H, Shiota K, Sasayama S (1997) Beneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation 95:245\u2013251","journal-title":"Circulation"},{"key":"754_CR75","doi-asserted-by":"publisher","first-page":"H1577","DOI":"10.1152\/ajpheart.00258.2005","volume":"289","author":"JF Wang","year":"2005","unstructured":"Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J, Chu V, Hampton TG, Crumpacker CS, Abelmann WH, Amende I, Morgan JP (2005) Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis. Am J Physiol Heart Circ Physiol 289:H1577\u20131583. \nhttps:\/\/doi.org\/10.1152\/ajpheart.00258.2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"754_CR76","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"754_CR77","volume-title":"Cochrane handbook for systematic reviews of interventions","author":"B Reeves","year":"2008","unstructured":"Reeves B, Deeks J, Higgins J, Wells G (2008) Including non-randomized studies. In: Higgins J, Green S (eds) Cochrane handbook for systematic reviews of interventions. Wiley, Chichester"},{"key":"754_CR78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ejphar.2010.04.037","volume":"640","author":"YC Li","year":"2010","unstructured":"Li YC, Ge LS, Yang PL, Tang JF, Lin JF, Chen P, Guan XQ (2010) Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction. Eur J Pharmacol 640:112\u2013116. \nhttps:\/\/doi.org\/10.1016\/j.ejphar.2010.04.037","journal-title":"Eur J Pharmacol"},{"key":"754_CR79","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.7150\/ijbs.7.1077","volume":"7","author":"V Sukumaran","year":"2011","unstructured":"Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, Suzuki K, Kodama M, Watanabe K (2011) Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2\/angiotensin 1-7\/mas receptor axis. Int J Biol Sci 7:1077\u20131092","journal-title":"Int J Biol Sci"},{"issue":"Suppl 1","key":"754_CR80","first-page":"S105","volume":"41","author":"H Tachikawa","year":"2003","unstructured":"Tachikawa H, Kodama M, Hui L, Yoshida T, Hayashi M, Abe S, Kashimura T, Kato K, Hanawa H, Watanabe K, Nakazawa M, Aizawa Y (2003) Angiotensin II type 1 receptor blocker, valsartan, prevented cardiac fibrosis in rat cardiomyopathy after autoimmune myocarditis. J Cardiovasc Pharmacol 41(Suppl 1):S105\u2013110","journal-title":"J Cardiovasc Pharmacol"},{"key":"754_CR81","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.jjcc.2015.09.008","volume":"68","author":"C Takamura","year":"2016","unstructured":"Takamura C, Suzuki J, Ogawa M, Watanabe R, Tada Y, Maejima Y, Akazawa H, Komuro I, Isobe M (2016) Suppression of murine autoimmune myocarditis achieved with direct renin inhibition. J Cardiol 68:253\u2013260. \nhttps:\/\/doi.org\/10.1016\/j.jjcc.2015.09.008","journal-title":"J Cardiol"},{"key":"754_CR82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000081267","volume":"73","author":"MI Wahed","year":"2005","unstructured":"Wahed MI, Watanabe K, Ma M, Yamaguchi K, Takahashi T, Tachikawa H, Kodama M, Aizawa Y (2005) Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy. Pharmacology 73:81\u201388. \nhttps:\/\/doi.org\/10.1159\/000081267","journal-title":"Pharmacology"},{"key":"754_CR83","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/cvr\/cvw219","volume":"113","author":"DI Bromage","year":"2017","unstructured":"Bromage DI, Pickard JM, Rossello X, Ziff OJ, Burke N, Yellon DM, Davidson SM (2017) Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res 113:288\u2013297. \nhttps:\/\/doi.org\/10.1093\/cvr\/cvw219","journal-title":"Cardiovasc Res"},{"key":"754_CR84","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2174\/1573403X14666180925095923","volume":"15","author":"D Muser","year":"2019","unstructured":"Muser D, Santangeli P, Selvanayagam JB, Nucifora G (2019) Role of cardiac magnetic resonance imaging in patients with idiopathic ventricular arrhythmias. Curr Cardiol Rev 15:12\u201323. \nhttps:\/\/doi.org\/10.2174\/1573403X14666180925095923","journal-title":"Curr Cardiol Rev"}],"container-title":["Basic Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00395-019-0754-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00395-019-0754-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T00:24:56Z","timestamp":1604017496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00395-019-0754-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["754"],"URL":"https:\/\/doi.org\/10.1007\/s00395-019-0754-x","relation":{},"ISSN":["0300-8428","1435-1803"],"issn-type":[{"value":"0300-8428","type":"print"},{"value":"1435-1803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"16 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"48"}}